0001209191-12-039313.txt : 20120727 0001209191-12-039313.hdr.sgml : 20120727 20120727142638 ACCESSION NUMBER: 0001209191-12-039313 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20120724 FILED AS OF DATE: 20120727 DATE AS OF CHANGE: 20120727 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Durata Therapeutics, Inc. CENTRAL INDEX KEY: 0001544116 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 871247903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 89 HEADQUARTERS PLAZA NORTH STREET 2: 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 09760 BUSINESS PHONE: 973-993-4867 MAIL ADDRESS: STREET 1: 89 HEADQUARTERS PLAZA NORTH STREET 2: 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 09760 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Canaan VIII LP CENTRAL INDEX KEY: 0001419148 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35599 FILM NUMBER: 12990102 BUSINESS ADDRESS: STREET 1: 2765 Sand Hill Road CITY: Menlo Park STATE: ca ZIP: 94025 BUSINESS PHONE: 650-854-8092 MAIL ADDRESS: STREET 1: 2765 Sand Hill Road CITY: Menlo Park STATE: ca ZIP: 94025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Canaan Partners VIII LLC CENTRAL INDEX KEY: 0001552200 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35599 FILM NUMBER: 12990101 BUSINESS ADDRESS: STREET 1: 285 RIVERSIDE AVENUE STREET 2: STE. 250 CITY: WESTPORT STATE: CT ZIP: 06880 BUSINESS PHONE: 2038550400 MAIL ADDRESS: STREET 1: 285 RIVERSIDE AVENUE STREET 2: STE. 250 CITY: WESTPORT STATE: CT ZIP: 06880 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Canaan Management, Inc. CENTRAL INDEX KEY: 0001555070 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35599 FILM NUMBER: 12990100 BUSINESS ADDRESS: STREET 1: 285 RIVERSIDE AVE. STREET 2: SUITE 250 CITY: WESTPORT STATE: CT ZIP: 06880 BUSINESS PHONE: 2038550400 MAIL ADDRESS: STREET 1: 285 RIVERSIDE AVE. STREET 2: SUITE 250 CITY: WESTPORT STATE: CT ZIP: 06880 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2012-07-24 2012-07-26 0 0001544116 Durata Therapeutics, Inc. DRTX 0001419148 Canaan VIII LP C/O CANAAN PARTNERS, 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 1 0 1 0 0001552200 Canaan Partners VIII LLC C/O CANAAN PARTNERS, 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 1 0 1 0 0001555070 Canaan Management, Inc. C/O CANAAN PARTNERS, 285 RIVERSIDE AVENUE, SUITE 250 WESTPORT CT 06880 1 0 0 0 Common Stock 2012-07-24 4 C 0 1346475 A 1346475 D Common Stock 2012-07-24 4 P 0 555555 9.00 A 1902030 D Series A Preferred Stock 2012-07-24 4 C 0 10771804 D Common Stock 1346475 0 D Stock Option (right to buy) 2.08 2012-02-28 4 A 0 6250 0.00 A 2022-02-27 Common Stock 6250 6250 I See footnote The Series A Preferred Stock has no expiration date and each share of Series A Preferred Stock converted automatically into 0.125 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Shares held directly by Canaan VIII L.P ("Canaan L.P."). Canaan Partners VIII LLC ("Canaan LLC"), the general partner of Canaan L.P., may be deemed to share voting, investment and dispositive power with respect to shares held by Canaan L.P., but disclaims beneficial ownership of the securities held by Canaan L.P. except to the extent of any pecuniary interest therein. Mr. Brenton K. Ahrens, a member and manager of Canaan LLC and a vice-president of Canaan Management, Inc. ("Canaan Management", and together with Canaan L.P. and Canaan LLC, the "Canaan Entities"), serves as the representative of the Canaan Entities on the Issuer's board of directors. This option was granted on February 28, 2012 to Mr. Ahrens with respect to 6,250 shares of common stock, vesting in 36 substantially equal monthly installments over a three year period, the first installment of which vested on March 28, 2012. Mr. Ahrens, pursuant to arrangements with Canaan LLC and Canaan Management, is contractually obligated to remit the value of any remuneration received for service as a director. Each of the Canaan Entities disclaims beneficial ownership in the stock options held by Mr. Ahrens, except to the extent, if any, of its pecuniary interest therein. This amended Form 4 is being filed solely to add Canaan Management, Inc. as a reporting person. Canaan VIII L.P., By: Canaan Partners VIII LLC, its general partner, By: /s/ Jaime E. Slocum, Attorney-in-Fact 2012-07-27 Canaan Partners VIII LLC, By: /s/ Jaime E. Slocum, Attorney-in-Fact 2012-07-27 Canaan Management, Inc., By: /s/ Eric A. Young, Vice-President 2012-07-27 EX-99 2 attachment1.htm EX-99 DOCUMENT

Exhibit 99

Form 4 Joint Filer Information

Names of Joint Filers:
Canaan VIII L.P.
Canaan Partners VIII LLC
Canaan Management, Inc.

Address of Joint Filers:
c/o Canaan Partners
285 Riverside Avenue, Suite 250
Westport, CT 06880

Designated Filer:
Canaan VIII L.P.
Issuer and Ticker Symbol:
Durata Therapeutics, Inc. [DRTX]
Date of Event:
July 24, 2012

Signatures of Joint Filers:
Canaan VIII L.P.
By: Canaan Partners VIII LLC
Its Sole General Partner
	By: /s/ Jaime E. Slocum, Attorney-in-Fact

Canaan Partners VIII LLC
By: /s/ Jaime E. Slocum, Attorney-in-Fact

Canaan Management, Inc.
By: /s/ Eric A. Young, Vice-President